SACS and Charlevoix-Saguenay spastic ataxia: We previously formally demonstrated this mechanism in ARSACS fibroblasts,7 and here, we precisely quantified sacsin protein reduction in PBMCs from patients with ARSACS and healthy carriers that had one or two pathogenic missense variants.